文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

COVID-19 后 2 年的后遗症。

Postacute sequelae of COVID-19 at 2 years.

机构信息

Clinical Epidemiology Center, Research and Development Service, VA Saint Louis Health Care System, Saint Louis, MO, USA.

Veterans Research and Education Foundation of Saint Louis, Saint Louis, MO, USA.

出版信息

Nat Med. 2023 Sep;29(9):2347-2357. doi: 10.1038/s41591-023-02521-2. Epub 2023 Aug 21.


DOI:10.1038/s41591-023-02521-2
PMID:37605079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10504070/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to postacute sequelae in multiple organ systems, but evidence is mostly limited to the first year postinfection. We built a cohort of 138,818 individuals with SARS-CoV-2 infection and 5,985,227 noninfected control group from the US Department of Veterans Affairs and followed them for 2 years to estimate the risks of death and 80 prespecified postacute sequelae of COVID-19 (PASC) according to care setting during the acute phase of infection. The increased risk of death was not significant beyond 6 months after infection among nonhospitalized but remained significantly elevated through the 2 years in hospitalized individuals. Within the 80 prespecified sequelae, 69% and 35% of them became not significant at 2 years after infection among nonhospitalized and hospitalized individuals, respectively. Cumulatively at 2 years, PASC contributed 80.4 (95% confidence interval (CI): 71.6-89.6) and 642.8 (95% CI: 596.9-689.3) disability-adjusted life years (DALYs) per 1,000 persons among nonhospitalized and hospitalized individuals; 25.3% (18.9-31.0%) and 21.3% (18.2-24.5%) of the cumulative 2-year DALYs in nonhospitalized and hospitalized were from the second year. In sum, while risks of many sequelae declined 2 years after infection, the substantial cumulative burden of health loss due to PASC calls for attention to the care needs of people with long-term health effects due to SARS-CoV-2 infection.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染可导致多个器官系统的急性后期后遗症,但证据主要局限于感染后 1 年。我们从美国退伍军人事务部建立了一个由 138818 名 SARS-CoV-2 感染患者和 5985227 名未感染对照组组成的队列,并对他们进行了 2 年的随访,以根据感染急性期的治疗环境来估计 COVID-19 急性后期后遗症(PASC)的 80 种预设风险。非住院患者感染后 6 个月后死亡风险无显著增加,但住院患者在 2 年内仍显著升高。在 80 种预设后遗症中,分别有 69%和 35%在非住院和住院患者感染后 2 年变得无显著意义。在 2 年内累积,PASC 导致非住院和住院患者每 1000 人分别损失 80.4(95%置信区间:71.6-89.6)和 642.8(95%置信区间:596.9-689.3)个伤残调整生命年(DALY);非住院和住院患者累积 2 年 DALY 中分别有 25.3%(18.9-31.0%)和 21.3%(18.2-24.5%)来自第 2 年。总之,尽管许多后遗症的风险在感染后 2 年下降,但由于 PASC 导致的健康损失的大量累积负担需要关注因 SARS-CoV-2 感染而长期存在健康影响的人群的护理需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/3e0bc8d8de03/41591_2023_2521_Fig15_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/84869f345f17/41591_2023_2521_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/b3ba7a23b310/41591_2023_2521_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/36753b3f894c/41591_2023_2521_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/cf166a6c8326/41591_2023_2521_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/356ad93849fa/41591_2023_2521_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/d084e944b734/41591_2023_2521_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/96059af986b7/41591_2023_2521_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/de7316f67bd4/41591_2023_2521_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/ef12713b1093/41591_2023_2521_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/634ee62753f4/41591_2023_2521_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/fbb656e4f3bd/41591_2023_2521_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/1eb49826f2c8/41591_2023_2521_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/ef65fae213fa/41591_2023_2521_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/d36b48870b63/41591_2023_2521_Fig14_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/3e0bc8d8de03/41591_2023_2521_Fig15_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/84869f345f17/41591_2023_2521_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/b3ba7a23b310/41591_2023_2521_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/36753b3f894c/41591_2023_2521_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/cf166a6c8326/41591_2023_2521_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/356ad93849fa/41591_2023_2521_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/d084e944b734/41591_2023_2521_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/96059af986b7/41591_2023_2521_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/de7316f67bd4/41591_2023_2521_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/ef12713b1093/41591_2023_2521_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/634ee62753f4/41591_2023_2521_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/fbb656e4f3bd/41591_2023_2521_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/1eb49826f2c8/41591_2023_2521_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/ef65fae213fa/41591_2023_2521_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/d36b48870b63/41591_2023_2521_Fig14_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a264/10504070/3e0bc8d8de03/41591_2023_2521_Fig15_ESM.jpg

相似文献

[1]
Postacute sequelae of COVID-19 at 2 years.

Nat Med. 2023-9

[2]
Three-year outcomes of post-acute sequelae of COVID-19.

Nat Med. 2024-6

[3]
Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras.

N Engl J Med. 2024-8-8

[4]
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.

Nat Med. 2022-11

[5]
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.

BMJ. 2023-4-25

[6]
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection.

Neurol Neuroimmunol Neuroinflamm. 2022-3-7

[7]
Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.

Lancet Infect Dis. 2024-3

[8]
Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy.

Obstet Gynecol. 2024-9-1

[9]
Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Infect Dis Clin North Am. 2022-6

[10]
Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.

JAMA Intern Med. 2023-6-1

引用本文的文献

[1]
Association between depression and three key COVID-19-related outcomes: The SHARE study.

Hum Vaccin Immunother. 2025-12

[2]
The impact of acute COVID-19 symptoms on insomnia: A longitudinal study among medical students.

Brain Behav Immun Health. 2025-7-22

[3]
Neuropsychiatric symptoms cluster as primary drivers of Long COVID complexity: a South Texas retrospective cohort study.

Front Neurol. 2025-7-23

[4]
Long COVID Syndrome, Mortality and Morbidity in Patients Hospitalized with COVID-19 From 16 Countries: The World Heart Federation Global COVID-19 Study.

Glob Heart. 2025-8-1

[5]
Sociodemographic factors, biomarkers and comorbidities associated with post-acute COVID-19 sequelae in UK Biobank.

Nat Commun. 2025-7-30

[6]
Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19.

Sci Rep. 2025-7-28

[7]
Impact of COVID-19 on antidepressant prescription: a matched cohort study using the National insurance claims database in Japan.

BMC Psychiatry. 2025-7-25

[8]
The short-, medium- and long-term risk and the multi-organ involvement of clinical sequelae after COVID-19 infection: a multinational network cohort study.

J R Soc Med. 2025-7-8

[9]
Insight into NeuroCOVID: neurofilament light chain (NfL) as a biomarker in post-COVID-19 patients with olfactory dysfunctions.

J Neurol. 2025-7-1

[10]
Assessing Neuropsychiatric Symptoms in Long COVID: A Retrospective Cohort Study from a South Texas Long COVID Clinic.

medRxiv. 2025-6-16

本文引用的文献

[1]
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.

BMJ. 2023-4-25

[2]
Prevention of long COVID: progress and challenges.

Lancet Infect Dis. 2023-7

[3]
Author Correction: Long COVID: major findings, mechanisms and recommendations.

Nat Rev Microbiol. 2023-6

[4]
Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.

BMJ. 2023-4-11

[5]
Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023.

JAMA. 2023-5-16

[6]
Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.

JAMA Intern Med. 2023-6-1

[7]
Long-term gastrointestinal outcomes of COVID-19.

Nat Commun. 2023-3-7

[8]
Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.

BMJ. 2023-3-7

[9]
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study.

Lancet Diabetes Endocrinol. 2023-2

[10]
Diabetes after SARS-CoV-2 infection.

Lancet Diabetes Endocrinol. 2023-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索